Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia

J Clin Oncol. 2023 Oct 1;41(28):4465-4468. doi: 10.1200/JCO.23.01141. Epub 2023 Jul 10.

Authors

Austin G Kulasekararaj^{1

2

3}, Roochi Trikha¹

Affiliations

¹ The Department of Haematological Medicine, King's College Hospital NHS, London, United Kingdom.
² National Institute for Health and Care Research and Wellcome King's Research Facility, London, United Kingdom.
³ King's College London, London, United Kingdom.

PMID: 37428990
DOI: 10.1200/JCO.23.01141

No abstract available

Publication types

Editorial
Comment

MeSH terms

Benzoates / therapeutic use
Humans
Hydrazines / adverse effects
Myelodysplastic Syndromes* / complications
Myelodysplastic Syndromes* / drug therapy
Thrombocytopenia* / drug therapy

Substances

eltrombopag
Benzoates
Hydrazines